Royce & Associates’s Centessa Pharmaceuticals CNTA Stock Holding History

Royce & Associates’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-278,064	Closed	-$11M	–	768
2026 Q1	$11M	Sell	278,064 -84,809	-23%	-$2.17M	0.11%	297
2025 Q4	$9.08M	Buy	362,873 +115,486	+47%	+$2.93M	0.09%	339
2025 Q3	$6M	Buy	+247,387	New	+$4.4M	0.06%	434

Royce & Associates's CNTA Position: Q2 2026 in Review

Royce & Associates sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 278,064 shares — an estimated $11M sold.

Royce & Associates first reported a position in CNTA in Q3 2025 and held it in 3 quarters. The position peaked at $11M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Royce & Associates reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Royce & Associates sold 278,064 Centessa Pharmaceuticals shares in Q2 2026, an estimated $11M.
Royce & Associates first reported a position in Centessa Pharmaceuticals in Q3 2025 and held it in 3 quarters.
Royce & Associates's Centessa Pharmaceuticals position peaked at $11M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.